Daniel A. Goldstein
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Daniel A. Goldstein has a total of 274 co-authors. Here are the top co-authors by number of shared publications:
Christopher R. Flowers
C Department of Hematology and Medical Oncology , Winship Cancer Institute, Emory University , Atlanta , GA , USA
15 shared publicationsNoa Gordon
Institute of Oncology, Davidoff Cancer Center, Rabin Medical Center, Israel
13 shared publicationsMoshe Leshno
Coller School of Management, Tel Aviv University, Tel Aviv, Israel
11 shared publicationsQiushi Chen
A Massachusetts General Hospital Institute for Technology Assessment , Boston , MA , USA
8 shared publicationsEli Rosenbaum
Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel
7 shared publications- Michal Sarfaty
Institute of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel
7 shared publications
Latest Publications
- 20 August 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
Variation in guideline decision-making: a cross-sectional study of oncology compendium panels
Introduction: Clinical practice guidelines influence coverage policy, utilization management, and health care spending. In oncology, some function as drug compendia that guide Medicare coverage of off-label therapies, yet little empirical work has examined their governance. Methods: We conducted a cross-sectional descriptive study using publicly available documentation to evaluate responses to 75 standardized external change requests submitted to 26 National Comprehensive Cancer Network (NCCN) disease-site panels concerning pembrolizumab or nivolumab dosing. Requests concerning subcutaneous formulations served as a comparator. We characterized request disposition, review timing, transparency, scope interpretation, and financial conflict-of-interest (FCOI) context. Results: By March 6, 2026, 10 of 75 dosing-related requests (13%) had been adopted, 51 (68%) rejected or determined to be outside panel scope, and 14 (19%) remained pending (median time to decision, 190 days). In contrast, requests concerning FDA-approved subcutaneous formulations were adopted in 52 of 53 cases (98%) and reviewed substantially more rapidly (median, 11 days). Public documentation incompletely described panel deliberations, voting, participation, and management of financial conflicts of interest. Conclusions: Standardized requests revealed operational heterogeneity and limitations in publicly available documentation within a CMS-recognized compendium, identifying opportunities to strengthen transparency and governance in coverage-relevant decision making.
- 20 August 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
Variation in guideline decision-making: a cross-sectional study of oncology compendium panels
Introduction: Clinical practice guidelines influence coverage policy, utilization management, and health care spending. In oncology, some function as drug compendia that guide Medicare coverage of off-label therapies, yet little empirical work has examined their governance. Methods: We conducted a cross-sectional descriptive study using publicly available documentation to evaluate responses to 75 standardized external change requests submitted to 26 National Comprehensive Cancer Network (NCCN) disease-site panels concerning pembrolizumab or nivolumab dosing. Requests concerning subcutaneous formulations served as a comparator. We characterized request disposition, review timing, transparency, scope interpretation, and financial conflict-of-interest (FCOI) context. Results: By March 6, 2026, 10 of 75 dosing-related requests (13%) had been adopted, 51 (68%) rejected or determined to be outside panel scope, and 14 (19%) remained pending (median time to decision, 190 days). In contrast, requests concerning FDA-approved subcutaneous formulations were adopted in 52 of 53 cases (98%) and reviewed substantially more rapidly (median, 11 days). Public documentation incompletely described panel deliberations, voting, participation, and management of financial conflicts of interest. Conclusions: Standardized requests revealed operational heterogeneity and limitations in publicly available documentation within a CMS-recognized compendium, identifying opportunities to strengthen transparency and governance in coverage-relevant decision making.
- Open Access
- 6 August 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Use and overuse of positron emission tomography for patients with metastatic colorectal cancer
In all healthcare systems, and particularly those that are resource limited, using diagnostic techniques efficiently is essential. According to consensus guidelines, standard computed tomography (CT) imaging without positron emission tomography (PET) is usually sufficient for the management of metastatic colorectal cancer (mCRC). This retrospective national cohort study evaluated the use of PET in mCRC management among members of Clalit Health Services (CHS, the largest Israeli health maintenance organization covering >50% of the Israeli population), utilizing the CHS central database. The cohort included CHS members diagnosed with mCRC between 2017 and 2022 (N = 998). The median number of PETs performed per patient was 5. Overall, during the follow-up period (up to 10/2024), 44% of patients underwent >5PETs, and the median number of PETs performed per patient per year was 2.2. In conclusion, our study identified a substantial overuse of PET in the management of mCRC in Israel, marking a divergence from clinical guidelines. More research is needed to assess this in other diseases and in other countries/regions.
- 6 August 2026
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Open AccessUse and overuse of positron emission tomography for patients with metastatic colorectal cancer
In all healthcare systems, and particularly those that are resource limited, using diagnostic techniques efficiently is essential. According to consensus guidelines, standard computed tomography (CT) imaging without positron emission tomography (PET) is usually sufficient for the management of metastatic colorectal cancer (mCRC). This retrospective national cohort study evaluated the use of PET in mCRC management among members of Clalit Health Services (CHS, the largest Israeli health maintenance organization covering >50% of the Israeli population), utilizing the CHS central database. The cohort included CHS members diagnosed with mCRC between 2017 and 2022 (N = 998). The median number of PETs performed per patient was 5. Overall, during the follow-up period (up to 10/2024), 44% of patients underwent >5PETs, and the median number of PETs performed per patient per year was 2.2. In conclusion, our study identified a substantial overuse of PET in the management of mCRC in Israel, marking a divergence from clinical guidelines. More research is needed to assess this in other diseases and in other countries/regions.
- Open Access
- 8 January 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 47, 100700
Accelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum
- 8 January 2026
- Published by Elsevier in Journal of Cancer Policy
- Vol. 47, 100700
Open AccessAccelerating cancer treatment optimisation: A multistakeholder roadmap from the Cancer Medicines Forum
- 28 October 2025
- Published by Elsevier in The Lancet Oncology
- Vol. 26 (11) , 1411-1413
Subcutaneous immunotherapy—a wolf in sheep's clothing?
- 28 October 2025
- Published by Elsevier in The Lancet Oncology
- Vol. 26 (11) , 1411-1413
Subcutaneous immunotherapy—a wolf in sheep's clothing?
- 28 July 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (9) , 701
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing
- 28 July 2025
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 22 (9) , 701
Clarifying the role of SONIA: supporting academic evidence on CDK4/6 inhibitor timing
- Open Access
- 21 July 2025
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 4 (3) , 16
Black Box Warning by the United States Food and Drug Administration: The Impact on the Dispensing Rate of Benzodiazepines
Background/objectives: In 9/2020, the United States Food and Drug Administration )FDA( posted a black box warning for all benzodiazepines, addressing their association with serious risks of abuse, addiction, physical dependence, and withdrawal reactions. We evaluated changes in benzodiazepine dispensing rate trends after this warning. Methods: The dataset of Clalit Health Services (Israel’s largest insurer, with 5 million members) was used to identify and collect benzodiazepine dispensing data for all patients who were dispensed these drugs at least once during the study period (1/2017–12/2021). The dispensing rate (number of patients who were dispensed benzodiazepines per month divided by the number of patients alive during that month) was calculated for each month in the study period. Linear regression and change point regression were used to review the change in trend before and after the black box warning. New users of benzodiazepines after the black box warning were analyzed by age. Results: A total of 639,515 patients using benzodiazepines were reviewed. The mean benzodiazepine dispensing rate per month was 0.21 and ranged from 0.17 (in 2/2017) to 0.24 (in 3/2020). No significant change in trend was observed before vs. after the black box warning (slopes of 0.00675 percentage points per month and 0.00001 percentage points per month, respectively; p = 0.38). The change point regression analysis identified a change point in 4/2019, which is prior to the black box warning. New users were younger after the black box warning compared to before this warning. Conclusions: The FDA black box warning did not affect the dispensing rate of benzodiazepines.
- 21 July 2025
- Published by MDPI AG in Pharmacoepidemiology
- Vol. 4 (3) , 16
Open AccessBlack Box Warning by the United States Food and Drug Administration: The Impact on the Dispensing Rate of Benzodiazepines
Background/objectives: In 9/2020, the United States Food and Drug Administration )FDA( posted a black box warning for all benzodiazepines, addressing their association with serious risks of abuse, addiction, physical dependence, and withdrawal reactions. We evaluated changes in benzodiazepine dispensing rate trends after this warning. Methods: The dataset of Clalit Health Services (Israel’s largest insurer, with 5 million members) was used to identify and collect benzodiazepine dispensing data for all patients who were dispensed these drugs at least once during the study period (1/2017–12/2021). The dispensing rate (number of patients who were dispensed benzodiazepines per month divided by the number of patients alive during that month) was calculated for each month in the study period. Linear regression and change point regression were used to review the change in trend before and after the black box warning. New users of benzodiazepines after the black box warning were analyzed by age. Results: A total of 639,515 patients using benzodiazepines were reviewed. The mean benzodiazepine dispensing rate per month was 0.21 and ranged from 0.17 (in 2/2017) to 0.24 (in 3/2020). No significant change in trend was observed before vs. after the black box warning (slopes of 0.00675 percentage points per month and 0.00001 percentage points per month, respectively; p = 0.38). The change point regression analysis identified a change point in 4/2019, which is prior to the black box warning. New users were younger after the black box warning compared to before this warning. Conclusions: The FDA black box warning did not affect the dispensing rate of benzodiazepines.
- Open Access
- 7 August 2024
- Published by BMJ in BMJ Oncology
- Vol. 3 (1) , e000391
Choosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer
Objective: Healthcare overuse is a major challenge for healthcare systems and patients worldwide. Professional guidelines such as the ‘Choosing Wisely’ guidelines have attempted to reduce specific examples of overuse. We examined the use of surveillance positron emission tomography CT (PETCT) in patients with colorectal cancer (CRC) treated with curative intent. Methods and analysis: We used the large Clalit Health Services dataset in Israel to identify patients with CRC who received adjuvant chemotherapy between January 2017 and December 2021. We examined the number of PETCTs performed for each patient. Results: We included 1799 patients in our study cohort. We distinguished localised from metastatic cases based on specific drugs administered or not administered during the follow-up period (ie, biologics). For the entire cohort, the median number of PETCTs performed per patient over the study period was 3364 (20.2%) patients underwent a single PETCT, 946 (52.6%) patients underwent ≥2 PETCTs and 25 patients underwent ≥10 PETCTs. If none or a single PETCT is considered ‘guideline-concordant’ during diagnosis and treatment of localised CRC, 69% of 4231 PETCTs performed were ‘guideline-discordant’. Conclusion: Despite the professional guidelines recommending against routine PETCT to monitor for recurrence following curative-intent treatment of CRC, there remains a large volume of guideline-discordant PETCTs, constituting healthcare overuse of an expensive diagnostic procedure.
- 7 August 2024
- Published by BMJ in BMJ Oncology
- Vol. 3 (1) , e000391
Open AccessChoosing Wisely in oncology: are guidelines effective at preventing unnecessary diagnostics? The example of surveillance positron emission tomography for patients with localised colorectal cancer
Objective: Healthcare overuse is a major challenge for healthcare systems and patients worldwide. Professional guidelines such as the ‘Choosing Wisely’ guidelines have attempted to reduce specific examples of overuse. We examined the use of surveillance positron emission tomography CT (PETCT) in patients with colorectal cancer (CRC) treated with curative intent. Methods and analysis: We used the large Clalit Health Services dataset in Israel to identify patients with CRC who received adjuvant chemotherapy between January 2017 and December 2021. We examined the number of PETCTs performed for each patient. Results: We included 1799 patients in our study cohort. We distinguished localised from metastatic cases based on specific drugs administered or not administered during the follow-up period (ie, biologics). For the entire cohort, the median number of PETCTs performed per patient over the study period was 3364 (20.2%) patients underwent a single PETCT, 946 (52.6%) patients underwent ≥2 PETCTs and 25 patients underwent ≥10 PETCTs. If none or a single PETCT is considered ‘guideline-concordant’ during diagnosis and treatment of localised CRC, 69% of 4231 PETCTs performed were ‘guideline-discordant’. Conclusion: Despite the professional guidelines recommending against routine PETCT to monitor for recurrence following curative-intent treatment of CRC, there remains a large volume of guideline-discordant PETCTs, constituting healthcare overuse of an expensive diagnostic procedure.
- 20 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (15) , 2713-2717
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?
- 20 May 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (15) , 2713-2717
Evaluating Trials of Adjuvant Therapy: Is There Benefit for People With Resected Renal Cancer?
- 1 February 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (2) , e230490
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
As of January 2021, pembrolizumab has received 39 US Food and Drug Administration (FDA) approvals for the treatment of cancer. Initially approved with weight-based dosing, there was a subsequent movement toward using fixed doses for all patients, first with 200 mg every 3 weeks, and more recently 400 mg every 6 weeks.1 It has previously been argued that the move to fixed dosing from weight-based dosing has maintained efficacy but increased costs.2 While lower doses of immune checkpoint inhibitors have been strongly recommended in other publications,3-5 we recognize that the FDA-approved dose levels and schedules remain the standard of care in many health care settings.
- 1 February 2023
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (2) , e230490
Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
As of January 2021, pembrolizumab has received 39 US Food and Drug Administration (FDA) approvals for the treatment of cancer. Initially approved with weight-based dosing, there was a subsequent movement toward using fixed doses for all patients, first with 200 mg every 3 weeks, and more recently 400 mg every 6 weeks.1 It has previously been argued that the move to fixed dosing from weight-based dosing has maintained efficacy but increased costs.2 While lower doses of immune checkpoint inhibitors have been strongly recommended in other publications,3-5 we recognize that the FDA-approved dose levels and schedules remain the standard of care in many health care settings.
- 10 January 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (2) , 170-172
Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy
- 10 January 2023
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (2) , 170-172
Cost Savings and Increased Access With Ultra-Low-Dose Immunotherapy